Benzinga | Apr 21, 2021 08:37AM EDT

Allogene Therapeutics Announces FDA Regenerative Medicine Advanced Therapy Designation Granted To ALLO-715, An AlloCAR T Cell Therapy In Development For Relapsed/Refractory Multiple Myeloma

Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T(tm)) therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to ALLO-715 in relapsed/refractory multiple myeloma. The FDA granted RMAT designation based on the potential of ALLO-715 to address the growing unmet need for patients who have failed other multiple myeloma therapies.